Patients with advanced HNSCC can receive anti-OX40 neoadjuvant treatment before surgery, which is not only safe, but can also increase the activation and proliferation of CD4+ and CD8+ T cells in the blood and tumors Duhen et al., 2021. This evidence concerns the gene CD4 and head and neck squamous cell carcinoma.